Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Oct 3, 2016
Arbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation's Patient Storytelling Campaign

Oct 1, 2016
Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting

View all »Events & Presentations

Sep 29, 2016 at 2:00 PM PT
Arbutus Biopharma HBV Product Pipeline Update

Aug 16, 2016
2016 Wedbush PacGrow Healthcare Conference